Climb Bio
CLYM
19 hedge funds and large institutions have $48.4M invested in Climb Bio in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 1 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
0.28% more ownership
Funds ownership: 62.58% → 62.86% (+0.28%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 20 → 19 (-1)
21% less capital invested
Capital invested by funds: $61M → $48.4M (-$12.6M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$418K |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$264K |
| 3 |
Morgan Stanley
New York
|
+$214K |
| 4 |
AI
Atom Investors
Austin,
Texas
|
+$11.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$573K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$92.6K |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$3.1K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$848 |
| 5 |
Millennium Management
New York
|
-$220 |
CLYM Hedge Fund Activity: Q1 2023 in Review
19 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q1 2023, worth a combined $48.4M — down 21% from $61M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CLYM and 0 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 7 added.
The largest buyer was Driehaus Capital Management, adding an estimated $418K. The largest seller was BML Capital Management, cutting an estimated $573K.
- 19 institutional investors held Climb Bio (CLYM) as of Q1 2023, down from 20 in Q4 2022.
- Funds reported $48.4M of Climb Bio stock for Q1 2023, down 21% quarter-over-quarter.
- 0 funds opened new Climb Bio positions in Q1 2023 and 1 closed out, a net change of -1 holder.
- The largest Climb Bio buyer in Q1 2023 was Driehaus Capital Management, an estimated $418K added.
- The largest Climb Bio seller in Q1 2023 was BML Capital Management, an estimated $573K sold.
Based on aggregated 13F filings for Q1 2023.